Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system

An adolescent with type 1 diabetes and a history of self-harm, which included intentional overdoses and insulin omission, presented with an insulin degludec overdose. She had been commenced on the ultra-long-acting insulin, degludec, with the aim of reducing ketoacidosis episodes in response to inte...

Full description

Bibliographic Details
Main Authors: Harmony Thompson, Helen Lunt, Cate Fleckney, Steven Soule
Format: Article
Language:English
Published: Bioscientifica 2018-06-01
Series:Endocrinology, Diabetes & Metabolism Case Reports
Online Access:https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-18-0044
id doaj-d19fccaf6a7b4144ad164c59a4816e17
record_format Article
spelling doaj-d19fccaf6a7b4144ad164c59a4816e172020-11-24T23:10:04ZengBioscientificaEndocrinology, Diabetes & Metabolism Case Reports2052-05732052-05732018-06-01111410.1530/EDM-18-0044Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring systemHarmony Thompson0Helen Lunt1Cate Fleckney2Steven Soule3Department of Endocrinology and Diabetes, Canterbury District Health Board, Christchurch, New ZealandDepartment of Endocrinology and Diabetes, Canterbury District Health Board, Christchurch, New Zealand; Department of Medicine, University of Otago Christchurch, Christchurch, New ZealandDepartment of Endocrinology and Diabetes, Canterbury District Health Board, Christchurch, New ZealandDepartment of Endocrinology and Diabetes, Canterbury District Health Board, Christchurch, New Zealand; Department of Medicine, University of Otago Christchurch, Christchurch, New ZealandAn adolescent with type 1 diabetes and a history of self-harm, which included intentional overdoses and insulin omission, presented with an insulin degludec overdose. She had been commenced on the ultra-long-acting insulin, degludec, with the aim of reducing ketoacidosis episodes in response to intermittent refusal to take insulin. Insulin degludec was administered under supervision as an outpatient. Because it was anticipated that she would attempt a degludec overdose at some stage, the attending clinicians implemented a proactive management plan for this (and related) scenarios. This included long-term monitoring of interstitial glucose using the Abbott Freestyle Libre flash glucose monitor. The patient took a witnessed overdose of 242 units of degludec (usual daily dose, 32 units). She was hospitalised an hour later. Inpatient treatment was guided primarily by interstitial glucose results, with capillary and venous glucose tests used as secondary measures to assess the accuracy of interstitial glucose values. Four days of inpatient treatment was required. The patient was managed with high glycaemic loads of food and also intermittent intravenous dextrose. No hypoglycaemia was documented during the admission. In summary, while a degludec overdose may require several days of inpatient management, in situations where proactive management is an option and the dose administered is relatively modest, it may be possible to avoid significant hypoglycaemia. In addition, this case demonstrates that inpatient interstitial glucose monitoring may have a role in managing insulin overdose, especially in situations where the effect of the insulin overdose on glucose levels is likely to be prolonged.https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-18-0044
collection DOAJ
language English
format Article
sources DOAJ
author Harmony Thompson
Helen Lunt
Cate Fleckney
Steven Soule
spellingShingle Harmony Thompson
Helen Lunt
Cate Fleckney
Steven Soule
Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system
Endocrinology, Diabetes & Metabolism Case Reports
author_facet Harmony Thompson
Helen Lunt
Cate Fleckney
Steven Soule
author_sort Harmony Thompson
title Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system
title_short Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system
title_full Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system
title_fullStr Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system
title_full_unstemmed Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system
title_sort insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the freestyle libre flash glucose monitoring system
publisher Bioscientifica
series Endocrinology, Diabetes & Metabolism Case Reports
issn 2052-0573
2052-0573
publishDate 2018-06-01
description An adolescent with type 1 diabetes and a history of self-harm, which included intentional overdoses and insulin omission, presented with an insulin degludec overdose. She had been commenced on the ultra-long-acting insulin, degludec, with the aim of reducing ketoacidosis episodes in response to intermittent refusal to take insulin. Insulin degludec was administered under supervision as an outpatient. Because it was anticipated that she would attempt a degludec overdose at some stage, the attending clinicians implemented a proactive management plan for this (and related) scenarios. This included long-term monitoring of interstitial glucose using the Abbott Freestyle Libre flash glucose monitor. The patient took a witnessed overdose of 242 units of degludec (usual daily dose, 32 units). She was hospitalised an hour later. Inpatient treatment was guided primarily by interstitial glucose results, with capillary and venous glucose tests used as secondary measures to assess the accuracy of interstitial glucose values. Four days of inpatient treatment was required. The patient was managed with high glycaemic loads of food and also intermittent intravenous dextrose. No hypoglycaemia was documented during the admission. In summary, while a degludec overdose may require several days of inpatient management, in situations where proactive management is an option and the dose administered is relatively modest, it may be possible to avoid significant hypoglycaemia. In addition, this case demonstrates that inpatient interstitial glucose monitoring may have a role in managing insulin overdose, especially in situations where the effect of the insulin overdose on glucose levels is likely to be prolonged.
url https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-18-0044
work_keys_str_mv AT harmonythompson insulindegludecoverdoseinanadolescentwithtype1diabetesproactivemanagementincludingmonitoringusingthefreestylelibreflashglucosemonitoringsystem
AT helenlunt insulindegludecoverdoseinanadolescentwithtype1diabetesproactivemanagementincludingmonitoringusingthefreestylelibreflashglucosemonitoringsystem
AT catefleckney insulindegludecoverdoseinanadolescentwithtype1diabetesproactivemanagementincludingmonitoringusingthefreestylelibreflashglucosemonitoringsystem
AT stevensoule insulindegludecoverdoseinanadolescentwithtype1diabetesproactivemanagementincludingmonitoringusingthefreestylelibreflashglucosemonitoringsystem
_version_ 1725608200473935872